Sun Pharma arm Taro recalls 17,100 kits of dandruff care kits in US

New Delhi: Drug major Sun Pharma arm Taro Pharmaceuticals USA Inc is recalling 17,100 kits of Kamedis Bio-Herbal Dandruff Care System in the US on account of being sub-potent drug. [caption id=“attachment_2159087” align=“alignleft” width=“380”]  Reuters[/caption] “Taro Pharmaceuticals USA Inc is recalling the drug because of it being subpotent drug: out of specification assay values on stability for the active ingredient, zinc pyrithione,” the latest Enforcement Report of health regulator USFDA has said. The therapeutic 2-step Kamedis Bio-Herbal Dandruff Care System is used for treating itching and flaking associated with dandruff and seborrheic dermatitis. The voluntary nationwide ongoing recall is a class III recall, US Food and Drug Administration (USFDA) said. According to USFDA, a class III recall is initiated in “a situation in which use of or exposure to a violative product is not likely to cause adverse health onsequences”.